Study to Evaluate the Safety and Pharmacokinetics of SPI-1005
A study to determine the safety, tolerability, and pharmacokinetics of SPI-1005 capsules in healthy adults.
Hearing Loss|Cancer
DRUG: SPI-1005|DRUG: Placebo
Number of Participants with Adverse Events as a Measure of Safety and Tolerability, The primary objective of this study was to evaluate the safety and tolerability of SPI-1005 (ebselen) in healthy subjects. Incidence and severity of Adverse Events were determined in all treatment and placebo groups., 1 month
Pharmacokinetics of SPI-1005 and its major metabolites in healthy subjects, Evaluate the single dose pharmacokinetic profile of SPI-1005 in healthy subjects including Tmax, Cmax, of the parent compound and major metabolites., 24 hours
A study to determine the safety, tolerability, and pharmacokinetics of SPI-1005 capsules in healthy adults.